Bolt Biotherapeutics (NASDAQ:BOLT) Share Price Passes Above 200 Day Moving Average of $1.09

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.09 and traded as high as $1.21. Bolt Biotherapeutics shares last traded at $1.19, with a volume of 154,904 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Bolt Biotherapeutics in a research report on Friday, March 22nd.

Bolt Biotherapeutics Price Performance

The firm has a 50-day simple moving average of $1.22 and a two-hundred day simple moving average of $1.09. The company has a market capitalization of $45.37 million, a price-to-earnings ratio of -0.65 and a beta of 0.99. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.15.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Thursday, March 21st. The company reported ($0.47) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.47). Bolt Biotherapeutics had a negative net margin of 878.58% and a negative return on equity of 51.18%. The business had revenue of $2.09 million for the quarter, compared to analyst estimates of $1.97 million. As a group, analysts predict that Bolt Biotherapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bolt Biotherapeutics stock. Newtyn Management LLC lifted its position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 2.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,020,000 shares of the company’s stock after buying an additional 20,000 shares during the period. Newtyn Management LLC owned approximately 2.69% of Bolt Biotherapeutics worth $1,061,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.